[go: up one dir, main page]

BR0012431A - Procyanidin oligomers and respective pharmaceutical compositions - Google Patents

Procyanidin oligomers and respective pharmaceutical compositions

Info

Publication number
BR0012431A
BR0012431A BR0012431-1A BR0012431A BR0012431A BR 0012431 A BR0012431 A BR 0012431A BR 0012431 A BR0012431 A BR 0012431A BR 0012431 A BR0012431 A BR 0012431A
Authority
BR
Brazil
Prior art keywords
procyanidin oligomers
procyanidin
pharmaceutical compositions
mmp
respective pharmaceutical
Prior art date
Application number
BR0012431-1A
Other languages
Portuguese (pt)
Inventor
Sang-Nyung Kim
Ho-Jeong Ahn
Sang-Ki Park
Moon-Moo Kim
Jung-Hun Kim
Hak-Mo Lee
Hyoung-Kook Park
Hye-Sung Cho
Seung-Yong Jeoung
Original Assignee
Lg Household & Health Care Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Household & Health Care Ltd filed Critical Lg Household & Health Care Ltd
Publication of BR0012431A publication Critical patent/BR0012431A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)

Abstract

"OLIGÈMEROS DE PROCIANIDINA E COMPOSIçõES FARMACêUTICAS RESPECTIVAS". A presente invenção proporciona oligómeros de procianidina com atividade biológica significativa contra metaloproteinase de matriz (MMP). Os oligómeros de procianidina podem ser isolados a partir do gênero Ulmus e outras plantas e compreendem oligómeros de procianidina desde triméricos até dodecaméricos de unidades monoméricas de flavan-3-ol. A presente invenção compreende métodos de uso do oligómero de procianidina no tratamento de metástases de tumor ou invasão, artrite reumatóide, diabetes, ulcerações córnea, epidérmica e gástrica, enrugamento da pele, periodontite, osteoporose; e na promoção da cura de ferimentos e queimaduras e outras doenças relacionadas à cerca das quais se pensa que elevados níveis fora de controle de MMP desempenhem um papel importante no progresso da doença."PROCIANIDIN OLIGAMERS AND RESPECTIVE PHARMACEUTICAL COMPOSITIONS". The present invention provides procyanidin oligomers with significant biological activity against matrix metalloproteinase (MMP). Procyanidin oligomers can be isolated from the genus Ulmus and other plants and comprise procyanidin oligomers from trimesters to dodecamers of flavan-3-ol monomer units. The present invention comprises methods of using the procyanidin oligomer in the treatment of tumor metastasis or invasion, rheumatoid arthritis, diabetes, corneal, epidermal and gastric ulcerations, skin wrinkling, periodontitis, osteoporosis; and in promoting the healing of wounds and burns and other related illnesses about which high levels out of MMP control are thought to play an important role in disease progression.

BR0012431-1A 1999-07-16 2000-07-14 Procyanidin oligomers and respective pharmaceutical compositions BR0012431A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-1999-0028877A KR100509119B1 (en) 1999-07-16 1999-07-16 Medicine comprising procyanidine as an effective agent
PCT/KR2000/000769 WO2001005397A1 (en) 1999-07-16 2000-07-14 Procyanidin oligomers inhibiting matrix metalloproteinases and medicine having effective composition of the same

Publications (1)

Publication Number Publication Date
BR0012431A true BR0012431A (en) 2002-09-24

Family

ID=19602329

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0012431-1A BR0012431A (en) 1999-07-16 2000-07-14 Procyanidin oligomers and respective pharmaceutical compositions

Country Status (9)

Country Link
EP (1) EP1196162A4 (en)
JP (1) JP2003504402A (en)
KR (1) KR100509119B1 (en)
CN (1) CN1364082A (en)
AU (1) AU5713000A (en)
BR (1) BR0012431A (en)
CA (1) CA2379489A1 (en)
MX (1) MXPA02000598A (en)
WO (1) WO2001005397A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1256335A1 (en) * 2001-05-10 2002-11-13 Cognis France S.A. Use of procyanidine oligomers
KR100439627B1 (en) * 2001-06-18 2004-07-12 주식회사 엘지생활건강 Composition for preventing and treating of skin wrinkles
US6906036B2 (en) * 2001-08-16 2005-06-14 Kimberly-Clark Worldwide, Inc. Anti-aging and wound healing compounds
KR100441131B1 (en) * 2001-08-22 2004-07-21 애경산업(주) Cosmetic compositons for acne skin containing natural fragrant oil
KR100441565B1 (en) * 2001-09-27 2004-07-23 이형주 Extracts of buckwheat and/or buchwheat chaff with anti-inflammatory effects and food composition comprising of the same
KR20030032359A (en) * 2001-10-17 2003-04-26 주식회사 엘지생활건강 Oral pharmaceutical composition for curing periodontal disease comprising ulmus cortex extract
KR100531472B1 (en) 2002-08-09 2005-11-28 주식회사 이롬 Cosmetic composition comprising extract of Rosa multiflora with antioxdative activity and preparation method of the extract
JP3533392B1 (en) 2003-03-27 2004-05-31 株式会社東洋新薬 External preparation for skin
JPWO2005092327A1 (en) * 2004-03-26 2008-02-07 アサヒビール株式会社 Periodontal ligament protectant
EP1616551A1 (en) * 2004-07-13 2006-01-18 L'oreal Cosmetic treatment for preventing or delaying the signs of skin ageing
FR2873026B1 (en) * 2004-07-13 2009-10-30 Oreal COSMETIC PROCESSING METHOD FOR PREVENTING OR DELAYING THE SIGNS OF AGING
CA2599295C (en) * 2005-02-25 2014-10-14 Nagasaki University Method of producing proanthocyanidin oligomer
US20060194746A1 (en) * 2005-02-28 2006-08-31 Peter Rohdewald Method and composition to inhibit infections with Helicobacter pylori by intake of procyanidins from type B and C
KR100687522B1 (en) * 2005-05-28 2007-02-27 한국화학연구원 Inflammatory disease therapeutic agent related to PGE2 activity containing 2,2-dimethyl-3-ester-4-alkoxy-6-alkyl aminobenzopyran derivative as active ingredient
US20060293258A1 (en) * 2005-06-23 2006-12-28 Peter Rohdewald Method and composition to treat skin ulcers
JP4942953B2 (en) * 2005-06-30 2012-05-30 サントリーホールディングス株式会社 Analysis method of procyanidins
JP5693243B2 (en) * 2008-03-05 2015-04-01 カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチＣｏｕｎｃｉｌ Ｏｆ Ｓｃｉｅｎｔｉｆｉｃ ＆ Ｉｎｄｕｓｔｒｉａｌ Ｒｅｓｅａｒｃｈ Flavonol compounds, biologically active extracts or fractions, pharmacological compositions, pharmaceuticals and production methods
JP5602416B2 (en) * 2009-11-13 2014-10-08 日油株式会社 Hyaluronidase activity inhibitor
KR101438517B1 (en) * 2012-06-13 2014-09-17 경희대학교 산학협력단 Composition for prevention, improvement and treatment of acne including flavan-3-ol multimer, derivative thereof or acceptable salt thereof as an active ingredient
CN104582699B (en) * 2012-08-07 2019-10-22 英德斯生物技术私营有限公司 Approaches to control diabetic foot ulcers, pressure ulcers, venous leg ulcers and related complications
US20140179774A1 (en) * 2012-12-26 2014-06-26 Industrial Technology Research Institute Methods for inhibition of shc-1/p66 to combat aging-related diseases
KR101760691B1 (en) * 2014-09-26 2017-07-24 연천군 Health functional food for preventing pancreatic adenocarcinoma
CN105998037A (en) * 2016-06-16 2016-10-12 汕头大学 Application of doxycycline to preparation of medicine for treating or preventing aging diseases
EP3501496A1 (en) 2017-12-22 2019-06-26 Cosmo Technologies Ltd. Liquid delivery composition
KR102074067B1 (en) * 2018-05-02 2020-02-06 주식회사 마크로케어 Capsule comprising salvianolic acid and the use of the same
JP2023094857A (en) * 2021-12-24 2023-07-06 サンスター株式会社 Hinokitiol-containing composition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1219732B (en) * 1988-06-28 1990-05-24 Tecnofarmaci Spa PROCYANIDOLIC OLIGOMERIC FRACTIONS, THEIR PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2672800B1 (en) * 1991-02-15 1995-03-10 Dolisos Lab NOVEL THERAPEUTIC USE OF PYCNOGENOLS FOR THE PREPARATION OF DRUGS WITH ANTI-INFLAMMATORY ACTIVITY.
WO1993024106A1 (en) * 1992-05-27 1993-12-09 L'oreal Composition comprising a proanthocyanidin oligomer encapsulated in a liposome
US5646178A (en) * 1992-10-09 1997-07-08 Jlb, Inc. Cranberry extract and biologically active compounds derived therefrom
US5554645A (en) * 1994-10-03 1996-09-10 Mars, Incorporated Antineoplastic cocoa extracts and methods for making and using the same
JP3450080B2 (en) * 1995-02-01 2003-09-22 有限会社野々川商事 Health foods and pharmaceuticals containing procyanidin
DE69633502T2 (en) * 1995-12-26 2006-02-23 Suntory Ltd. PROCYANIDINE AS THE ACTIVE INGREDIENT AGAINST GRAVITY
FR2770228B1 (en) * 1997-10-27 1999-12-10 Greentech Sa PROCESS FOR OBTAINING PROANTHOCYANIDINE OLIGOMERS BY BIOFERMENTATION AND THEIR USE IN COSMETIC, DIETETIC, PHARMACEUTICAL, CHEMICAL AND FOOD COMPOSITIONS

Also Published As

Publication number Publication date
KR20010010154A (en) 2001-02-05
EP1196162A4 (en) 2003-06-18
WO2001005397A1 (en) 2001-01-25
MXPA02000598A (en) 2003-07-21
EP1196162A1 (en) 2002-04-17
KR100509119B1 (en) 2005-08-18
JP2003504402A (en) 2003-02-04
AU5713000A (en) 2001-02-05
WO2001005397A8 (en) 2001-04-05
CA2379489A1 (en) 2001-01-25
CN1364082A (en) 2002-08-14

Similar Documents

Publication Publication Date Title
BR0012431A (en) Procyanidin oligomers and respective pharmaceutical compositions
ES2215056T3 (en) THERAPEUTIC AGENT WITH A BOTULINIC NEUROTOXIN.
RU2608492C2 (en) Hyaluronidase and method of its application
Zeka et al. New hydrogels enriched with antioxidants from saffron crocus can find applications in wound treatment and/or beautification
BR0009012A (en) Medication for the treatment of diabetes
Singkhorn et al. Induction of keratinocyte migration by ECa 233 is mediated through FAK/Akt, ERK, and p38 MAPK signaling
BR0107613A (en) Blockade of axon growth mediated by nogo receptor
ATE370749T1 (en) COMPOSITIONS OF NUCLIC ACID AND VISCOSITY-INCREASING POLYMER PVP, FOR USE IN GENE THERAPY
US6689349B1 (en) Skin protection agents containing a fragment mixture produced from hyaluronic acid by hydrolysis
MXPA02006679A (en) Pharmaceutical composition.
IL154888A (en) Non-aqueous pharmaceutical gel composition containing at least one vitamin d or one vitamin d analogue and at least one corticosteroid and its use in the manufacture of a medicament for treatment of psoriasis
BR0210838A (en) Compound, pharmaceutical formulation, use of a compound, methods for preventing and / or treating conditions associated with glycogen synthase kinase-3, and disease, and contraceptive medication, and processes for preparing a compound.
WO2009080272A1 (en) Use of a neurotoxic component of a clostridium botulinum toxin complex to reduce or prevent side effects
Odeku et al. Formulation of floating metronidazole microspheres using cassava starch (Manihot esculenta) as polymer
Ol’shannikova et al. Preparation of papain complexes with chitosan microparticles and evaluation of their stability using the enzyme activity level
ES2088956T3 (en) MULTIFRACTIONABLE TABLET STRUCTURE.
GR1002847B (en) Use of micropostol and/or micropostol acid for the preparation of a medicine for the therapeutic treatiment of problems related to the erection
NO172043C (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE N-2,3-BUTADIENYL-TRIAMIOAL CANDY DERIVATIVES
NO20033441L (en) Polymer conjugates of neubastine and their use
Nolting Non-traumatic removal of the nail and simultaneous treatment of onychomycosis
KR970706831A (en) MEDICINAL COMPOSITION FOR DIABETES
BR9803974A (en) Chromans replaced by sulfonamide, processes for its preparation, its use as a medicine and pharmaceutical preparations containing the same
PT840794E (en) A medicament containing at least a portion of the CITOMEGALOVIRUS UL84 PROTEIN, USING POLIPEPTIDEES ACCORDING TO THE UL84 PROTEIN AMINO ACID SEQUENCE AND PROCESS FOR THE INTRODUCTION OF UL84 IN TARGET CELLS
WO2017034288A1 (en) Cosmetic composition for preventing or ameliorating skin damage caused by ultraviolet light
WO2023148204A1 (en) Oral dosage form with a gastro resistant capsule shell

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.